Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peer Group | 1 | 2024 | 156 | 0.860 |
Why?
|
| Students, Medical | 1 | 2024 | 130 | 0.830 |
Why?
|
| Metamorphosis, Biological | 2 | 2009 | 15 | 0.560 |
Why?
|
| Triiodothyronine | 2 | 2009 | 32 | 0.550 |
Why?
|
| Blood Platelets | 3 | 2020 | 77 | 0.480 |
Why?
|
| Neuromuscular Junction | 5 | 2006 | 33 | 0.450 |
Why?
|
| Rana catesbeiana | 4 | 2009 | 30 | 0.440 |
Why?
|
| Receptors, Nicotinic | 7 | 2007 | 106 | 0.380 |
Why?
|
| Locomotion | 2 | 2014 | 97 | 0.340 |
Why?
|
| Swimming | 1 | 2009 | 38 | 0.320 |
Why?
|
| Thyrotropin | 1 | 2008 | 17 | 0.310 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 43 | 0.310 |
Why?
|
| Menopause | 1 | 2008 | 56 | 0.300 |
Why?
|
| Alzheimer Disease | 3 | 2020 | 905 | 0.300 |
Why?
|
| Potassium Channels | 3 | 2002 | 75 | 0.290 |
Why?
|
| Tryptophan | 5 | 2004 | 73 | 0.260 |
Why?
|
| Tail | 2 | 2003 | 6 | 0.250 |
Why?
|
| Burnout, Professional | 1 | 2024 | 19 | 0.240 |
Why?
|
| Receptors, Cholinergic | 4 | 2004 | 28 | 0.230 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2003 | 1 | 0.230 |
Why?
|
| Puerto Rico | 2 | 2024 | 1378 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2024 | 80 | 0.220 |
Why?
|
| Torpedo | 7 | 2004 | 41 | 0.220 |
Why?
|
| Choroid | 1 | 2022 | 10 | 0.210 |
Why?
|
| Vertebrates | 1 | 2022 | 29 | 0.210 |
Why?
|
| Amino Acid Substitution | 6 | 2006 | 132 | 0.200 |
Why?
|
| Neuroglia | 2 | 2002 | 124 | 0.200 |
Why?
|
| Patch-Clamp Techniques | 9 | 2014 | 223 | 0.200 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2019 | 95 | 0.200 |
Why?
|
| Animals | 23 | 2022 | 15081 | 0.190 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 935 | 0.190 |
Why?
|
| Amyloidosis | 1 | 2020 | 33 | 0.180 |
Why?
|
| Retina | 2 | 2002 | 280 | 0.180 |
Why?
|
| Parkinson Disease | 1 | 2020 | 178 | 0.160 |
Why?
|
| Acetylcholine | 5 | 2006 | 73 | 0.160 |
Why?
|
| Glaucoma | 1 | 2019 | 85 | 0.150 |
Why?
|
| Membrane Potentials | 6 | 2003 | 223 | 0.150 |
Why?
|
| Oocytes | 8 | 2007 | 146 | 0.150 |
Why?
|
| Larva | 3 | 2003 | 124 | 0.140 |
Why?
|
| Chemical Phenomena | 1 | 2016 | 54 | 0.140 |
Why?
|
| Hemeproteins | 1 | 2016 | 14 | 0.140 |
Why?
|
| Magnetics | 1 | 2016 | 36 | 0.140 |
Why?
|
| Muscles | 2 | 1988 | 82 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2721 | 0.140 |
Why?
|
| Bufo marinus | 3 | 1991 | 6 | 0.130 |
Why?
|
| Protein Subunits | 3 | 2004 | 87 | 0.130 |
Why?
|
| Brain | 2 | 2020 | 1346 | 0.130 |
Why?
|
| Quinine | 1 | 2014 | 10 | 0.130 |
Why?
|
| Ion Channels | 3 | 2006 | 71 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2014 | 14 | 0.120 |
Why?
|
| Membrane Lipids | 2 | 2007 | 33 | 0.120 |
Why?
|
| Ventral Tegmental Area | 1 | 2014 | 36 | 0.120 |
Why?
|
| Myasthenic Syndromes, Congenital | 2 | 2006 | 4 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 79 | 0.120 |
Why?
|
| Ion Channel Gating | 3 | 2004 | 83 | 0.120 |
Why?
|
| Young Adult | 1 | 2024 | 4268 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2014 | 314 | 0.110 |
Why?
|
| Adult | 2 | 2024 | 11712 | 0.110 |
Why?
|
| Cocaine | 1 | 2014 | 232 | 0.100 |
Why?
|
| Xenopus laevis | 7 | 2007 | 73 | 0.100 |
Why?
|
| Humans | 9 | 2024 | 37093 | 0.100 |
Why?
|
| Mutation | 3 | 2006 | 1095 | 0.090 |
Why?
|
| Male | 6 | 2024 | 20025 | 0.090 |
Why?
|
| Synaptic Transmission | 2 | 2006 | 146 | 0.090 |
Why?
|
| Synapses | 1 | 1991 | 180 | 0.080 |
Why?
|
| Cheek | 1 | 2009 | 14 | 0.080 |
Why?
|
| Electrophysiological Phenomena | 1 | 2009 | 19 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2004 | 188 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 6 | 2007 | 408 | 0.080 |
Why?
|
| Kinetics | 4 | 2006 | 708 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2007 | 51 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 455 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 295 | 0.070 |
Why?
|
| Cell Membrane | 3 | 2004 | 381 | 0.070 |
Why?
|
| Female | 2 | 2024 | 20969 | 0.070 |
Why?
|
| Potassium Compounds | 1 | 1984 | 4 | 0.060 |
Why?
|
| Fluorides | 1 | 1984 | 19 | 0.060 |
Why?
|
| Bungarotoxins | 4 | 2007 | 21 | 0.060 |
Why?
|
| Sodium | 1 | 1984 | 103 | 0.060 |
Why?
|
| Xenopus | 4 | 2004 | 48 | 0.060 |
Why?
|
| Niflumic Acid | 1 | 2003 | 1 | 0.060 |
Why?
|
| Chloride Channels | 1 | 2003 | 3 | 0.060 |
Why?
|
| Extracellular Space | 1 | 2003 | 35 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2003 | 63 | 0.050 |
Why?
|
| Ranidae | 1 | 2002 | 12 | 0.050 |
Why?
|
| Muscle Weakness | 1 | 2002 | 7 | 0.050 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2002 | 61 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2022 | 209 | 0.050 |
Why?
|
| Nicotine | 1 | 2004 | 257 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 2379 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2004 | 513 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 119 | 0.050 |
Why?
|
| Cholesterol | 1 | 2001 | 205 | 0.050 |
Why?
|
| Calcium | 1 | 2003 | 480 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 1180 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2020 | 103 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2004 | 1568 | 0.040 |
Why?
|
| Neural Conduction | 1 | 1999 | 17 | 0.040 |
Why?
|
| Aged | 2 | 2008 | 6741 | 0.040 |
Why?
|
| Neurons | 1 | 2004 | 1175 | 0.040 |
Why?
|
| Gene Expression | 3 | 2007 | 674 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1371 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 286 | 0.030 |
Why?
|
| Miniature Postsynaptic Potentials | 1 | 2014 | 4 | 0.030 |
Why?
|
| Benzophenanthridines | 1 | 2014 | 9 | 0.030 |
Why?
|
| Prazosin | 1 | 2014 | 11 | 0.030 |
Why?
|
| Adrenergic Agents | 1 | 2014 | 8 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2014 | 50 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 32 | 0.030 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2014 | 12 | 0.030 |
Why?
|
| Phenylephrine | 1 | 2014 | 36 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 33 | 0.030 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2014 | 22 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2014 | 184 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 177 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2014 | 53 | 0.030 |
Why?
|
| Protein Structure, Secondary | 2 | 2004 | 183 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 122 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 120 | 0.030 |
Why?
|
| Middle Aged | 1 | 2008 | 10129 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2004 | 269 | 0.030 |
Why?
|
| Models, Molecular | 3 | 2001 | 808 | 0.030 |
Why?
|
| Indoles | 1 | 2014 | 158 | 0.030 |
Why?
|
| Dopamine | 1 | 2014 | 245 | 0.030 |
Why?
|
| Electric Conductivity | 2 | 2000 | 51 | 0.030 |
Why?
|
| Binding Sites | 2 | 2004 | 651 | 0.020 |
Why?
|
| Protein Conformation | 2 | 2003 | 389 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1991 | 142 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 1039 | 0.020 |
Why?
|
| Mice | 2 | 2014 | 5913 | 0.020 |
Why?
|
| Pedigree | 1 | 2006 | 79 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 52 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2006 | 79 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2006 | 101 | 0.020 |
Why?
|
| Cesium | 1 | 1984 | 7 | 0.020 |
Why?
|
| Microinjections | 1 | 2004 | 57 | 0.020 |
Why?
|
| Permeability | 1 | 1984 | 67 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2003 | 66 | 0.010 |
Why?
|
| Potassium | 1 | 1984 | 112 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 282 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2003 | 89 | 0.010 |
Why?
|
| Tolbutamide | 1 | 2002 | 5 | 0.010 |
Why?
|
| Rana pipiens | 1 | 2002 | 62 | 0.010 |
Why?
|
| Motor Endplate | 1 | 2002 | 3 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 56 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 2002 | 58 | 0.010 |
Why?
|
| Electromyography | 1 | 2002 | 55 | 0.010 |
Why?
|
| Molecular Probes | 1 | 2001 | 23 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 93 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2002 | 83 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 196 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 972 | 0.010 |
Why?
|
| Allosteric Site | 1 | 2000 | 11 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 160 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 286 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 893 | 0.010 |
Why?
|
| Time Factors | 1 | 1984 | 1742 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 409 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1518 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 3483 | 0.010 |
Why?
|
| Child | 1 | 2002 | 3131 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 5363 | 0.010 |
Why?
|